Search results for " Absence seizures"

showing 2 items of 2 documents

Rufinamide in children and adults with Lennox-Gastaut syndrome: first Italian multicenter experience

2010

This is the first multicenter Italian experience with rufinamide as an adjunctive drug in children, adolescents and adults with Lennox-Gastaut syndrome. The patients were enrolled in a prospective, add-on, open-label treatment study from 11 Italian centers for children and adolescent epilepsy care. Forty-three patients (26 males, 17 females), aged between 4 and 34 years (mean 15.9 ± 7.3, median 15.0), were treated with rufinamide for a mean period of 12.3 months (range 3-21 months). Twenty patients were diagnosed as cryptogenic and 23 as symptomatic. Rufinamide was added to the baseline therapy at the starting dose of 10mg/kg body weight, evenly divided in two daily doses and then increased…

MalePediatricsLennox-Gastaut syndromeAtypical absence seizuresRufinamideLennox–Gastaut syndrome; Rufinamide; Orphan drug; Pediatrics; Epilepsy; Drop attacksInfantilePediatricsSpasmsEpilepsyRufinamideDrop attacks; Epilepsy; Lennox-Gastaut syndrome; Orphan drug; Pediatrics; Rufinamide; Adolescent; Adult; Anticonvulsants; Child; Child Preschool; Drug Therapy Combination; Female; Humans; Intellectual Disability; Italy; Lennox Gastaut Syndrome; Male; Spasms Infantile; Treatment Outcome; Triazoles; Valproic Acid; Young Adult; Neurology (clinical); NeurologyChildPediatricValproic AcidDrop attacksGeneral MedicineSettore MED/39 - Neuropsichiatria InfantileTreatment OutcomeItalyNeurologyAnesthesiaChild PreschoolCombinationVomitingAnticonvulsantsDrug Therapy CombinationFemalemedicine.symptomSpasms Infantilemedicine.drugAdultmedicine.medical_specialtyAdolescentClinical NeurologyIrritabilityYoung AdultDrug TherapyIntellectual DisabilitymedicineHumanspediatrics epilepsyPreschoolAdverse effectLennox–Gastaut syndrome; rufinamide; orphan drug; pediatrics epilepsy; drop attacks; refractory epilepsy.EpilepsyOrphan drugbusiness.industryLennox Gastaut SyndromeValproic Acidrefractory epilepsyTriazolesmedicine.diseaseNeurology (clinical)businessLennox–Gastaut syndromeLennox–Gastaut syndrome
researchProduct

Antiabsence effects of carbenoxolone in two genetic animal models of absence epilepsy (WAG/Rij rats and lh/lh mice).

2005

Carbenoxolone (CBX), the succinyl ester of glycyrrhetinic acid, is an inhibitor of gap junctional intercellular communication. We have tested its possible effects upon two genetic animal models of epilepsy (WAG/Rij rats and lethargic (lh/lh) mice). Systemic administration of CBX was unable to significantly affect the occurrence of absence seizures in WAG/Rij rats. In particular, intravenous (5-40 mg/kg) or intraperitoneal (i.p.; 10-80 mg/kg) administration of CBX was unable to significantly modify the number and duration of spike-wave discharges (SWDs) in WAG/Rij rats, whereas the bilateral microinjection (0.05, 0.1, 0.5 and 1 microg/0.5 microl) of CBX into nucleus reticularis thalami (NRT)…

Malemedicine.medical_specialtyTime FactorsCarbenoxoloneConnexinConnexinsCellular and Molecular Neurosciencechemistry.chemical_compoundEpilepsyMiceMice Neurologic MutantsInternal medicinemedicineAnimalsGlycyrrhizinMicroinjectionGap junctionsPharmacologyDose-Response Relationship DrugGap junctionElectroencephalographyRats Inbred StrainsEpilepsy Carbenoxolone WAG/Rij rat Lethargic mouse Gap junction Connexin Absence seizuresmedicine.diseaseRatsDisease Models AnimalEndocrinologymedicine.anatomical_structurechemistryEpilepsy AbsenceGene Expression RegulationThalamic NucleiSystemic administrationCarbenoxoloneepilepsyAutoradiographyNucleusmedicine.drugGap junctions; Carbenoxolone ; epilepsyNeuropharmacology
researchProduct